title: Development of sarcoidosis during etanercept therapy.
authors.affiliation: Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain.
authors.forename: Marcos A
authors.initials: MA
authors.lastname: González-López
authors.forename: Ricardo
authors.initials: R
authors.lastname: Blanco
authors.forename: M Carmen
authors.initials: MC
authors.lastname: González-Vela
authors.forename: Héctor
authors.initials: H
authors.lastname: Fernández-Llaca
authors.forename: Vicente
authors.initials: V
authors.lastname: Rodríguez-Valverde
mesh_terms: D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016207:Cytokines / Q000502:physiology; D000068800:Etanercept; D006099:Granuloma / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009363:Neoplasm Proteins / Q000009:adverse effects / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000627:therapeutic use; D012507:Sarcoidosis / Q000139:chemically induced* / Q000503:physiopathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000503:physiopathology; D053319:Tumor Necrosis Factor Decoy Receptors
chemical_list: D018501:Antirheumatic Agents; D016207:Cytokines; D007074:Immunoglobulin G; D009363:Neoplasm Proteins; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; D000068800:Etanercept